MedTrace Logo

Pharmacokinetics of Dactinomycin in Young Patients With Cancer

NCT00900354 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2013-08-12

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood in the laboratory from patients with cancer receiving dactinomycin may help doctors learn how dactinomycin works in the body and how patients will respond to treatment.

PURPOSE: This laboratory study is evaluating the pharmacokinetics of dactinomycin in young patients with cancer.

Conditions

  • Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

GENETIC

molecular genetic technique

OTHER

mass spectrometry

OTHER

pharmacological study

Sponsors & Collaborators

  • Children's Cancer and Leukaemia Group

    lead OTHER

Principal Investigators

  • Gareth Veal · University of Newcastle Upon-Tyne

  • Alan Boddy, PhD · University of Newcastle Upon-Tyne

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30

Countries

  • Ireland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00900354 on ClinicalTrials.gov